GlassScriptPhysician profile
Ahmed B Arshad
NPI 1154461531
$6,284.78
in general payments reported to CMS, 2019-2025
31 companies · $577 in 2025
The $577 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $373 · 2021: $2,431 · 2022: $1,030 · 2023: $699 · 2024: $955 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.98 |
| Education | $147.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,879.58 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy Symmetry Model 8103 Generator |
| Abbvie INC. | $1,459.34 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Allergan, INC. | $683.07 | 2020-2022 | |
| Emd Serono, INC. | $556.22 | 2019-2025 | Mavenclad |
| Ucb, INC. | $288.86 | 2019-2025 | Briviact |
| Novartis Pharmaceuticals Corporation | $176.64 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $168.12 | 2019-2025 | Austedo Xr, Austedo |
| Argenx US, INC. | $133.57 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Harmony Biosciences LLC | $128.79 | 2022-2024 | |
| Amgen INC. | $110.73 | 2021-2025 | Uplizna, Aimovig |
| Alexion Pharmaceuticals, INC. | $74.06 | 2022 | |
| Lilly USA, LLC | $68.35 | 2019-2024 | Reyvow, Emgality |
| Biogen, INC. | $65.87 | 2020-2021 | |
| Genentech USA, INC. | $49.19 | 2020-2024 | Ocrevus |
| Biohaven Pharmaceutical Holding Company LTD. | $45.96 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $42.66 | 2023-2024 | |
| Lundbeck LLC | $42.20 | 2021-2022 | |
| Pfizer INC. | $35.70 | 2019-2024 | |
| Sk Life Science, INC. | $35.27 | 2020-2023 | |
| Avanir Pharmaceuticals, INC. | $33.64 | 2021 | |
| Depuy Synthes Sales INC. | $32.40 | 2021 | |
| Novo Nordisk INC | $26.45 | 2021 | |
| Csl Behring | $22.50 | 2022 | |
| Acadia Pharmaceuticals INC | $17.83 | 2022 | |
| Genzyme Corporation | $17.32 | 2020 | |
| Eisai INC. | $16.50 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.23 | 2020 | |
| Corcept Therapeutics | $16.08 | 2025 | Korlym |
| Arbor Pharmaceuticals, INC. | $15.96 | 2021 | |
| Orthofix Medical, INC. | $13.09 | 2020 | |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.